Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned a consensus recommendation of “Hold” from the nine brokerages that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $41.33.

A number of analysts have issued reports on the company. Zacks Investment Research raised Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, September 5th. ValuEngine downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Robert W. Baird reaffirmed a “sell” rating and set a $22.00 price target on shares of Theravance Biopharma in a report on Wednesday, November 1st. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the stock a “buy” rating in a report on Wednesday, October 25th. Finally, BidaskClub downgraded Theravance Biopharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 14,670 shares of Theravance Biopharma stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the sale, the executive vice president now directly owns 134,327 shares of the company’s stock, valued at approximately $4,133,241.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.10% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in TBPH. QS Investors LLC acquired a new stake in shares of Theravance Biopharma during the second quarter worth about $100,000. Ameritas Investment Partners Inc. increased its position in shares of Theravance Biopharma by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 230 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Theravance Biopharma by 570.7% during the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 4,383 shares in the last quarter. Aperio Group LLC acquired a new stake in shares of Theravance Biopharma during the second quarter worth about $205,000. Finally, Amalgamated Bank acquired a new stake in shares of Theravance Biopharma during the second quarter worth about $214,000. 83.84% of the stock is owned by institutional investors.

Theravance Biopharma (NASDAQ:TBPH) opened at $28.45 on Friday. Theravance Biopharma has a fifty-two week low of $23.15 and a fifty-two week high of $43.44. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21.

COPYRIGHT VIOLATION WARNING: “Theravance Biopharma, Inc. (TBPH) Given Average Recommendation of “Hold” by Brokerages” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/26/theravance-biopharma-inc-tbph-given-average-recommendation-of-hold-by-brokerages.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.